Cell-based Assays Market Size, Share & Trends Analysis Report By End-use (Pharma & Biotech Companies, CROs), By Products & Service (Reagent, Assay Kits), By Application, By Region,- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The global cell-based assays market size was exhibited at USD 16.95 billion in 2023 and is projected to hit around USD 39.43 billion by 2033, growing at a CAGR of 8.81% during the forecast period of 2024 to 2033.

Key Takeaways:

• The North American region dominated the global industry in 2023 and accounted for the maximum share of more than 45.0% of the overall revenue. 
• The assay kits products & services segment dominated the global industry in 2023 and accounted for the maximum share of more than 38.85% of the overall revenue.
• The drug discovery application segment dominated the global industry in 2023 and accounted for the maximum share of more than 40.10% of the overall revenue.
• The pharmaceutical & biotechnology companies end-use segment dominated the global industry in 2023 and accounted for the highest share of more than 55.0% of the overall revenue.

Cell-based Assays Market Report Scope

The market is witnessing high growth prospects due to factors such as growing demand for drug discovery, rising need for research in biotechnology, and increasing incidence of infectious diseases, cancer, autoimmune, and genetic disorders. Cell-based assays are commonly adopted in the drug discovery process for validating potential drug candidates. Assays are also employed for lead profiling, cellular signaling, and toxicity analysis. For instance, The Annexin V-Cy3 apoptosis detection kit (by Cell Biologics) aids in the detection of apoptosis by fluorescence.

The COVID‐19 pandemic disrupted the continuity of research processes, major clinical trials, and drug discovery processes. Many researchers across the globe implemented effective and less time-consuming research methodologies to make up for the research backlogs. Many cell-based assays are devised for the detection of COVID-19 infection as well. Several tests are approved by the FDA for emergency use across the globe. For instance, in May 2023, U.S. FDA granted Emergency Use Authorization(EUA) for the T-Detect COVID-19 routine T-cell test (by Adaptive Biotechnologies). It is an NGS-based test that aids in the identification of T-cells that recognize SARS-CoV-2 antigens for confirmation of recent infections.

Cell-based drug screening assays have been extensively used in drug discovery research to choose favorable drug candidates from a huge compound library. These assays are a broad spectrum of assays and are diverse with an array of factors for consideration in any given drug development process. Increasing developments in drug discovery are likely to offer a favorable environment for industry growth. For instance, in September 2022, researchers at the Fraunhofer Institute developed Proxidrugs to utilize a cells-based waste disposal system as a potential therapeutic option for infections, cancer, and Alzheimer’s disease.

Furthermore, many private firms offer customized assays that suit individual research needs with a focus on a particular therapeutic regime to combat a particular disease. For instance, in November 2023, Menarini Silicon Biosystems, launched its CELLSEARCH, a laboratory-developed test to aid the enumeration of multiple myeloma cells using a blood sample. This also facilitates physicians in the identification of high-risk patients. In addition, a growing number of product launches coupled with technological developments are estimated to accelerate industry growth. For instance, in August 2022, LifeNet Health LifeSciences announced the launch of its new cell-based assay services to aid in drug discovery and development.

Segments Insights:

Products & Services Insights

On the basis of products & services, the global industry has been further categorized into reagents, assay kits, microplates, probes & labels, instruments & software, and cell lines. The assay kits products & services segment dominated the global industry in 2023 and accounted for the maximum share of more than 38.85% of the overall revenue. The segment is projected to expand further at the fastest growth rate retaining its leading position throughout the forecast period. This can be attributed to its utility in various biopharmaceutical applications.

These particular assay kits significantly cut down ambiguity by offering reliable outcomes in diagnostics, and therefore have a high demand. Moreover, its comprehensive approach of offering all the consumables for the assay drives the segment. For instance, instaCELL Skin Sensitization Assay Kit (by Accelerate) detects early key events of the skin sensitization process, thereby the KeratinoSens (keratinocyte cell lines) express the luciferase reporter gene upon activation.

Application Insights

On the basis of applications, the global industry has been further categorized into basic research, drug discovery, and other applications. The drug discovery application segment dominated the global industry in 2023 and accounted for the maximum share of more than 40.10% of the overall revenue. This growth is attributed to the growing demand for novel therapeutic drugs for the treatment of various diseases across the globe. The growth of the drug discovery segment is boosted by a rise in the number of studie for therapeutic drug discovery and growing competition for FDA approvals among the market players.

For instance, in August 2022, FDA approved cell-based gene therapy to treat subjects with Beta-thalassemia requiring a regular blood transfusion process. Furthermore, basic research application is expected to garner a significant industry share over the forecast period. To better understand numerous cellular events in health and illness, cell-based assays act as the core of life sciences research. These assays are used to identify an impact or event within a cell, study gene, protein, or whole-cell activities and the regulatory mechanisms controlling them, and screen for possible inducers or inhibitors of biological processes.

End-use Insights

The pharmaceutical & biotechnology companies end-use segment dominated the global industry in 2023 and accounted for the highest share of more than 55.0% of the overall revenue. In the pharmaceutical industry, cell-based assays are effective for assessing the impact of external stimuli or pharmacological molecules on general cellular function. Furthermore, to choose promising lead molecule candidates from thousands of chemical compound libraries, cell-based drug screening assays have been widely employed in drug discovery research. Such broad applications of cell-based assays in the pharmaceutical industry drive segment growth.

The academic & research institutes end-use segment is expected to witness the fastest CAGR during the forecast period. The growth can be attributed to the rising adoption of these assays for cell-based research and the devising of novel assay-based diagnostics. For instance, in May 2022, the Genetics Institute of America and OneCellDx entered into a strategic agreement for the commercialization of its OneCellDx OncoPredikt kit, which enables the detection of Homologous Recombination Deficiency in cancer patients. Moreover, cell-based assays encourage research in the field of cancer, immunology, stem cells, immunology, and others.

Regional Insights

On the basis of geographies, the global industry has been further categorized into North America, Middle East & Africa, Latin America, Europe, and the Asia Pacific. The North American region dominated the global industry in 2023 and accounted for the maximum share of more than 45.0% of the overall revenue. The region is anticipated to expand further at a steady growth rate maintaining its leading position throughout the forecast period. Market growth in the North American region is mainly attributed to the extensive research carried out in various research institutes collaboratively sponsored by academic research institutes and pharmaceutical giants across the region.

For instance, in April 2022, Labcorp signed a collaboration with Xcell Biosciences, Inc., for the advancement of critical laboratory work focused on improving the safety and efficacy of Cell & Gene Therapies (CGTs) to help effective introduction of innovative CGTs to the market. The rising demand for novel therapeutic drugs in the Asia Pacific is expected to play a major role in the regional market growth. Furthermore, rapid infrastructural development and increasing R&D investment by governments are other factors that are boosting regional growth. Many research studies are sponsored by pharmaceutical giants in the region, resulting in increased demand for cell-based assays for various applications.

Some of the prominent players in the Cell-based assays market include:

BD

Bio-Rad Laboratories, Inc.

Corning Inc.

Charles River Laboratories

Danaher Corp.

F. Hoffmann-La Roche Ltd. (Roche Holdings AG)

Lonza

Merck KGaA

Promega Corp.

Thermo Fisher Scientific Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global cell-based assays market.

Products & Services

• Reagents
• Assay Kits

• • Cell Growth Assays
  • Reporter Gene Assays
  • Cell Death Assays
  • Second Messenger Assays

• Microplates
• Probes & Labels
• Instruments & Software
• Cell Lines

• • Primary Cell Lines
  • Stem Cell Lines
  • Immortalized Cell Lines

Application

• Basic Research
• Drug Discovery
• Other Applications

End-use

• Pharmaceutical and Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)